Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
312.58 -2.23   -0.71%881,6411.5M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 9/23/2016

Latest News Headlines for Biogen Inc

No News for Biogen Inc

Peers Information HelpBIIB Biogen Inc vs. Peers

BIIB
Biogen Inc
2.03%
-0.95%
Shire PLC (ADR)
-22.73%
Novo Nordisk A/S (ADR)
-21.94%
Allergan plc
-6.06%
Abbott Laboratories
BIIB
Biogen Inc
0.00%
Shire PLC (ADR)
0.40%
Novo Nordisk A/S (ADR)
2.02%
Allergan plc
0.00%
Abbott Laboratories
2.47%
-0.71%
BIIB
Biogen Inc
-0.57%
Shire PLC (ADR)
-1.51%
Novo Nordisk A/S (ADR)
Allergan plc
0.21%
-0.07%
Abbott Laboratories
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

https://www.biogen.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open312.58
Previous Close314.81
Day High317.32
Day Low312.11
52 Week High8/2/2016 | 333.65
52 Week Low6/27/2016 | 223.0211
% Off 52 Week High-6.32%
% Off 52 Week Low40.16%
Beta (5 Yr)0.94
Volatility Avg9/23/2016 | 36.08
10-Day Avg. Volume1,482,008
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2016 | 17.13
P/E Ratio6/30/2016 | 18.2
Market CapLarge Cap | 68.5B
Shares Outstanding219.12M
Float218.5M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.16M
Short Ratio1.8
Short % of Float0.99%
As of 8/31/2016
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.